Hydrocortisone Hualan Pharmaceuticals (Hydrocortisone)

Hydrocortisone Hualan Pharmaceuticals is indicated for several medical conditions that require glucocorticoid therapy.

• Adrenal insufficiency (primary or secondary) requiring hormone replacement.
• Congenital adrenal hyperplasia to suppress excess androgen production.
• Inflammatory conditions such as dermatitis, arthritis, or asthma exacerbations.
• Replacement therapy in patients with cortisol deficiency after adrenalectomy.
• Management of severe allergic reactions when oral glucocorticoid therapy is appropriate.

• Hydrocortisone acts as an agonist at intracellular glucocorticoid receptors. After oral absorption, the drug diffuses into cells and binds to the cytosolic receptor complex, causing translocation to the nucleus. This complex binds glucocorticoid response elements on DNA, modulating transcription of anti‑inflammatory proteins and suppressing pro‑inflammatory cytokines. The net effect reduces leukocyte migration, capillary permeability, and immune activation, providing systemic glucocorticoid activity.

Oral hydrocortisone may be associated with a range of adverse reactions, varying in frequency and severity.

Common

• Mild gastrointestinal discomfort, nausea, or loss of appetite.
• Transient elevation of blood glucose levels, often without symptoms.
• Fluid retention that may lead to mild peripheral edema.
• Mood alterations including irritability, anxiety, or difficulty sleeping.
• Skin thinning or easy bruising, especially with prolonged use.
• Increased susceptibility to allergic reactions or delayed wound healing.

Serious

• Significant hyperglycemia that may precipitate or worsen diabetes mellitus.
• Suppression of the hypothalamic‑pituitary‑adrenal (HPA) axis, increasing risk of adrenal crisis on abrupt discontinuation.
• Severe or opportunistic infections resulting from immunosuppressive activity.

When prescribing oral hydrocortisone, clinicians should evaluate several safety considerations to minimize risk.

• Assess baseline blood glucose and monitor for hyperglycemia during therapy.
• Evaluate for active infections; avoid use in uncontrolled systemic infection.
• Review patient history for hypertension, osteoporosis, or peptic ulcer disease.
• Consider tapering the dose when discontinuing after prolonged therapy to prevent adrenal insufficiency.
• Use caution in pregnant or breastfeeding individuals; benefits must outweigh potential risks.
• Avoid concomitant use with strong CYP3A4 inducers that may reduce drug exposure.

Hydrocortisone can interact with other medicines, altering its effectiveness or increasing the risk of adverse effects.

Avoid

• Strong CYP3A4 inducers such as rifampin, carbamazepine, or phenytoin, which may markedly reduce hydrocortisone plasma concentrations.
• High‑dose systemic antifungals (e.g., ketoconazole, itraconazole) that can increase glucocorticoid levels and precipitate toxicity.

Use with caution

• Non‑steroidal anti‑inflammatory drugs (NSAIDs) that may heighten the risk of gastrointestinal bleeding.
• Anticoagulants (warfarin) because glucocorticoids can affect clotting factor synthesis.
• Vaccines, especially live attenuated vaccines, due to possible reduced immune response.
• Diabetic medications, as hydrocortisone may raise blood glucose and require dose adjustments.